NCT05948644View on ClinicalTrials.gov

The Safety, Tolerability, and Pharmacokinetics of TPN171H Tablets in Patients With Pulmonary Arterial Hypertension

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 8, 2019

Primary Completion Date

October 14, 2020

Study Completion Date

October 14, 2020

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

TPN171H

TPN171H 2.5mg TPN171H 5mg TPN171H 10mg

Trial Locations (1)

Unknown

Fu Zhu, Shanghai

All Listed Sponsors
collaborator

Shanghai Institute of Materia Medica, Chinese Academy of Sciences

OTHER

lead

Vigonvita Life Sciences

INDUSTRY

NCT05948644 - The Safety, Tolerability, and Pharmacokinetics of TPN171H Tablets in Patients With Pulmonary Arterial Hypertension | Biotech Hunter | Biotech Hunter